ABIONYX Pharma S.A.
ABNX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €2,120 | €2,256 | €2,344 | €2,512 |
| % Growth | -6% | -3.8% | -6.7% | – |
| Cost of Goods Sold | €1,890 | €1,659 | €2,041 | €1,883 |
| Gross Profit | €230 | €597 | €303 | €629 |
| % Margin | 10.8% | 26.5% | 12.9% | 25% |
| R&D Expenses | €690 | €1,675 | €1,311 | €2,143 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €1,880 | €1,758 | €1,551 | €1,145 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€10 | €0 | €0 | -€1,475 |
| Operating Expenses | €2,560 | €3,433 | €2,862 | €1,813 |
| Operating Income | -€2,330 | -€2,341 | -€2,587 | -€1,184 |
| % Margin | -109.9% | -103.8% | -110.4% | -47.1% |
| Other Income/Exp. Net | €30 | €48 | €49 | -€86 |
| Pre-Tax Income | -€2,300 | -€2,293 | -€2,538 | -€1,270 |
| Tax Expense | €0 | -€636 | -€450 | €0 |
| Net Income | -€2,300 | -€2,293 | -€2,088 | -€1,270 |
| % Margin | -108.5% | -101.6% | -89.1% | -50.6% |
| EPS | -0.067 | -0.066 | -0.065 | -0.041 |
| % Growth | -0.6% | -2% | -59.2% | – |
| EPS Diluted | -0.067 | -0.066 | -0.065 | -0.041 |
| Weighted Avg Shares Out | 34,677 | 34,677 | 32,205 | 31,170 |
| Weighted Avg Shares Out Dil | 34,677 | 34,677 | 32,205 | 31,170 |
| Supplemental Information | – | – | – | – |
| Interest Income | €17 | €74 | €30 | €53 |
| Interest Expense | €58 | €19 | €42 | €138 |
| Depreciation & Amortization | €63 | €4,327 | €205 | €47 |
| EBITDA | -€2,278 | €2,051 | -€2,291 | -€1,137 |
| % Margin | -107.4% | 90.9% | -97.7% | -45.3% |